Quarterly report · Q3
4564.TEDINET S100SU6F
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥466m | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥700m | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | −¥973m | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | −¥905m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | −¥986m | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥929m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥985m | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | −¥912m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥987m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥913m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥987m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | −¥913m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥931m | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.4bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥275m | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥656m | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥656m | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.1bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥599m | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-4.68 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.27 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.74 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.55 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.3% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥206,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥206,000 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥261m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥466m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥466m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥175m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥634,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥427,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥206,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥537m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥466m |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥466m |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥206,000 |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | −¥712m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥172,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥172,000 |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥290m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥691m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥691m |
| jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥79m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥9m |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥172,000 |
| jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2022-04-01 → 2022-12-31 | −¥536m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥700m |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥700m |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥172,000 |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | −¥615m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 312
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)やまと監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)南出 浩一 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)木村 喬 | |
| Number of submission | FilingDateInstant | 1 | |
| Business revenue (5-year summary) | Prior1YTDDuration | 699689000 | JPY |
| Business revenue (5-year summary) | CurrentYTDDuration | 466006000 | JPY |
| Business revenue (5-year summary) | Prior1YearDuration | 1134903000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | -928906000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | -986439000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | -1133099000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | -913197000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | -987329000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | -1118644000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | -913197000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | -987329000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | -1118644000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 1051988000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 656129000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 855169000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 1443979000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 931166000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 1511438000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | -4.74 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | -4.68 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | -5.81 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.681 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.623 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.515 | |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | -1.55 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | -1.27 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 217643700 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 217643700 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 217643700 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 217643700 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 217627900 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 2176279 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 15800 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 217643700 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 2176279 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |